WASHINGTON , July 31, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a leading global life sciences and diagnostics innovator, today announced that Jonathan Leiken has been appointed Senior Vice President and General Counsel, effective August 25, 2025 . Mr. Leiken will report directly to President and Chief Executive Officer Rainer Blair and will serve as an executive officer and a member of the Danaher Leadership... Read More

WASHINGTON , July 22, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a leading global life sciences and diagnostics innovator, today announced that Matthew Gugino , currently Group Chief Financial Officer of the Company's Life Sciences Innovations Group and Vice President of Financial Planning & Analysis, will succeed Matthew McGrew as Danaher's Chief Financial Officer effective February 28 th , 2026. Following the... Read More

WASHINGTON , July 22, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended June 27, 2025. Key Second Quarter 2025 Results Net earnings were $555 million , or $0.77 per diluted common share and non-GAAP adjusted diluted net earnings per common share were $1.80 . Revenues increased 3.5% year-over-year to $5.9 billion and non-GAAP core revenue increased 1.5%... Read More

WASHINGTON , June 27, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a leading global life sciences and diagnostics innovator, today announced that Martin Stumpe will be appointed Chief Technology and AI Officer, effective October 1, 2025 . He will report directly to Rainer Blair , President and Chief Executive Officer. This appointment marks a pivotal step in Danaher's digital transformation and its ambition to lead... Read More

WASHINGTON , June 27, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a leading global life sciences and diagnostics innovator, today announced that Greg Milosevich has been appointed by its Board of Directors to be Executive Vice President of Danaher with responsibility for its Life Sciences business, effective July 1, 2025. Mr. Milosevich has served as Vice President and Group Executive of the Life Sciences... Read More

WASHINGTON , June 17, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the second quarter 2025 on Tuesday, July 22, 2025 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations. The call and an accompanying slide presentation will be webcast on... Read More

MARLBOROUGH, Mass. / Jun 02, 2025 / Business Wire / SCIEX , a global leader in life science analytical technologies and operating company of Danaher Corporation (NYSE: DHR), announces three software ecosystem enhancements at ASMS. These developments will present new ways to acquire data, new standards for performance, and new practices to extract elevated insights, all supporting the theme that “all science is data science... Read More

MARLBOROUGH, Mass. / Jun 02, 2025 / Business Wire / SCIEX , a global leader in life science analytical technologies and operating company of Danaher Corporation (NYSE: DHR), and Evosep Biosystems , a global leader in proteomics solutions, enter a reseller agreement to co-sell SCIEX mass spectrometry systems with the newly announced Evosep Eno , for standardized high-throughput proteomics. The reseller agreement empowers... Read More

MARLBOROUGH, Mass. / Jun 02, 2025 / Business Wire / At ASMS 2025, SCIEX , a global leader in life science analytical technologies and operating company of Danaher Corporation (NYSE: DHR), launches the ZenoTOF 8600 system , setting a new standard in accurate mass quantitation. The system is competitive in identification, superior in quantitation, and enhances structural understanding so scientists can now confidently quantify... Read More

Danaher has entered a partnership with AstraZeneca to scale precision medicine, including developing the next generation of AI-powered diagnostics This partnership aims to create a framework for rapid diagnostics research, development and commercialization Danaher, through its Centers for Enabling Precision Medicine, will provide support in all aspects of the development cycle across diagnostic modalities WASHINGTON , May... Read More

N of 1 therapy uniquely developed, on demand, for infant with life-threatening rare metabolic disorder in six months Results published in The New England Journal of Medicine and showcased at American Society of Gene & Cell Therapy Annual Meeting FARGO, N.D. & CORALVILLE, Iowa / May 15, 2025 / Business Wire / Aldevron , a global leader in the production of DNA, RNA and protein, together with Integrated DNA Technologies (IDT),... Read More

WASHINGTON , May 7, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair , will be presenting at the at the Bank of America Securities Health Care Conference in Las Vegas, Nevada on Thursday, May 15, 2025 at 10:00 a.m. PT . The event will be simultaneously webcast on www.danaher.com . ABOUT DANAHER Danaher is a leading global life sciences and diagnostics... Read More

WASHINGTON , May 6, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.32 per share of its common stock, payable on July 25, 2025 to holders of record on June 27, 2025 . ABOUT DANAHER Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve... Read More

Kytopen and Aldevron announce collaboration to expedite cell therapy manufacturing by combining their novel technologies. High transgene expression and improved safety profile of Aldveron's Nanoplasmid ™ vector technology and the gentle gene-delivery of Kytopen's Flowfect Tx™ platform with unlimited scale, together offer enhanced CRISPR-mediated T-cell engineering resulting in high yields. A poster summarizing the data will... Read More

WASHINGTON , April 22, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended March 28, 2025. Key First Quarter 2025 Results Net earnings were $1.0 billion , or $1.32 per diluted common share and non-GAAP adjusted diluted net earnings per common share were $1.88 . Revenues decreased 1.0% to $5.7 billion and non-GAAP core revenue was flat year-over-year. Operating... Read More

WASHINGTON , March 20, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the first quarter 2025 on Tuesday, April 22, 2025 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations. The call and an accompanying slide presentation will be webcast... Read More

The new DxC 500i Analyzer Offers Flexibility and Scalability with Broad Chemistry and Immunoassay Assay Menu BREA, Calif. , March 10, 2025 /PRNewswire/ -- Beckman Coulter Diagnostics, a clinical diagnostics leader, today announced that the new DxC 500i Clinical Analyzer, an integrated clinical chemistry and immunoassay... Read More

WASHINGTON , Feb. 25, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair , will be presenting at the TD Cowen Healthcare Conference in Boston, Massachusetts on Wednesday, March 5, 2025 at 10:30 a.m. ET . The event will be simultaneously webcast and can be accessed on the "Investors" section of Danaher's website, www.danaher.com , under the subheading... Read More

WASHINGTON , Feb. 20, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that it has appointed Charles Lamanna to its Board of Directors and to the Board's Science & Technology Committee. Mr. Lamanna is currently Corporate Vice President, Business & Industry Copilot at Microsoft (NASDAQ: MSFT), where he drives product innovation in AI-powered business applications, low-code platforms, and autonomous agents.... Read More

WASHINGTON , Feb. 20, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.32 per share of its common stock, payable on April 25, 2025 to holders of record on March 28, 2025 . This reflects an 18.5% increase over the previous dividend payment of $0.27 . ABOUT DANAHER Danaher is a leading global life sciences and diagnostics... Read More

WASHINGTON , Jan. 29, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the fourth quarter and full year 2024. All results in this release reflect only continuing operations unless otherwise noted. Key Fourth Quarter 2024 Results Net earnings were $1.1 billion , or $1.49 per diluted common share and non-GAAP adjusted diluted net earnings per common share were $2.14 . Revenues... Read More

FARGO, N.D. / Jan 21, 2025 / Business Wire / Aldevron, a global leader in the production of DNA, RNA and protein, has launched its latest innovation, Alchemy™ cell-free DNA technology. This revolutionary technology represents a significant advancement in synthetic DNA manufacturing, offering a cell-free, enzymatic process to... Read More

New, Fully Automated, High-Throughput RUO Assays offered on Beckman Coulter Immunoassay Analyzers BREA, Calif. , Jan. 15, 2025 /PRNewswire/ -- Beckman Coulter Diagnostics, a global leader in advanced diagnostics, today announced availability of new Research Use Only (RUO) blood-based biomarker immunoassays designed to advance... Read More

WASHINGTON , Jan. 13, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") announced that its President and Chief Executive Officer, Rainer M. Blair , will comment tomorrow on the Company's fourth quarter 2024 performance in a presentation at the J.P. Morgan Healthcare Conference at 11:15 a.m. PT . For the fourth quarter 2024, estimated revenues are anticipated to increase in the low-single digit percent... Read More

Partnership seeks to improve patient outcomes and experience through novel digital and diagnostic solutions. Investment aligns with Danaher's mission to accelerate the transition to precision medicine with AI-enabled diagnostics. WASHINGTON , Jan. 9, 2025 /PRNewswire/ -- Danaher Diagnostics LLC and Danaher Ventures LLC, two subsidiaries of Danaher Corporation (NYSE: DHR) ("Danaher"), a global science and technology... Read More

WASHINGTON , Jan. 6, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that its President and Chief Executive Officer, Rainer M. Blair , will be presenting at the J.P. Morgan Healthcare Conference in San Francisco, California on Tuesday, January 14, 2025 at 11:15 a.m. PT . The event will be simultaneously webcast and can be accessed on the "Investors" section of Danaher's website, www.danaher.com , under the... Read More

WASHINGTON , Jan. 2, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the fourth quarter 2024 on Wednesday, January 29, 2025 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations. The call and an accompanying slide presentation will be... Read More

WASHINGTON , Dec. 10, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.27 per share of its common stock, payable on January 31, 2025 to holders of record on December 27, 2024 . ABOUT DANAHER Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to... Read More

WASHINGTON , Nov. 26, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair , will be presenting at the Evercore ISI HealthCONx Conference in Coral Gables, Florida on Wednesday, December 4, 2024 at 3:25 p.m. ET . The event will be simultaneously webcast on www.danaher.com . ABOUT DANAHER Danaher is a leading global life sciences and diagnostics innovator,... Read More

WASHINGTON , Oct. 22, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended September 27, 2024. All results in this release reflect only continuing operations unless otherwise noted. Key Third Quarter 2024 Results Net earnings were $818 million , or $1.12 per diluted common share and non-GAAP adjusted diluted net earnings per common share were $1.71 . Revenues... Read More

WASHINGTON , Sept. 19, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the third quarter 2024 on Tuesday, October 22, 2024 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations. The call and an accompanying slide presentation will be webcast... Read More

BREA, Calif. and TEL AVIV, Israel , Sept. 17, 2024 /PRNewswire/ -- Beckman Coulter, a clinical diagnostics leader, and Scopio Labs, a medtech company that develops digital cell morphology workflow solutions, today jointly announced expansion of its long-term partnership to include a global distribution agreement of Scopio's Full-Field Bone Marrow Aspirate™ (FF-BMA) Application. Scopio's X100 / X100HT with FF-BMA Application... Read More

WASHINGTON , Sept. 10, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.27 per share of its common stock, payable on October 25, 2024 to holders of record on September 27, 2024 . ABOUT DANAHER Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to... Read More

WASHINGTON , Sept. 4, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") confirmed its previously issued guidance for the third quarter and full year 2024 ahead of a previously scheduled analyst event. The Company provides forecasted sales only on a non-GAAP core revenue basis because of the difficulty in estimating the other components of GAAP revenue, such as currency translation, acquisitions and... Read More

WASHINGTON , Aug. 26, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) will host a live video webcast of its Diagnostics Investor and Analyst Meeting in Washington, D.C. on September 5, 2024 beginning at approximately 10:00 a.m. ET . The event will be hosted by Julie Sawyer Montgomery , Executive Vice President, Diagnostics. A link to the webcast and accompanying slide presentation will be available on the "Investors"... Read More

BREA, Calif. , July 25, 2024 /PRNewswire/ -- Beckman Coulter Diagnostics, a clinical diagnostics leader, today announced that the DxI 9000 Immunoassay Analyzer* was honored during Premier, Inc.'s annual supplier Innovation Celebration at its 2024 Breakthroughs Conference and Exhibition . The Innovation Celebration recognizes... Read More

WASHINGTON , July 23, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended June 28 , 2024. All results in this release reflect only continuing operations unless otherwise noted. Key Second Quarter 2024 Results Net earnings were $907 million , or $1.22 per diluted common share and non-GAAP adjusted diluted net earnings per common share were $1.72 . Revenues... Read More

DH Diagnostics LLC Centers aim to accelerate drug development by speeding and streamlining development and commercialization of companion diagnostics. Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathologists (CAP)-certified laboratories will bring technologies and assays from multiple Danaher subsidiaries together under a single roof. WASHINGTON , July 17, 2024 /PRNewswire/ -- Danaher... Read More

WASHINGTON , July 16, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher" or the "Company"), the global life sciences and diagnostics innovator, today published its 2024 Sustainability Report which conveys the depth and scope of Danaher's sustainability program and highlights important milestones the Company achieved during the past year. "At the heart of everything we do at Danaher is our commitment to... Read More

Predictive tools will seek to reduce leading cause of failure rates in clinical trials of oncology drugs. Integrated AI and microscopy expected to lead to better understanding of tumor structures and treatment strategies. New technology will work to capture and analyze the highly heterogeneous tumor microenvironment. WASHINGTON , July 11, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a global science and technology... Read More

Ideally Suited for Satellite and Independent Labs, the new DxC 500i Analyzer Offers Flexibility, Scalability and Data Commutability with Extensive Chemistry and Immunoassay Assay Menu The New DxC 500i Analyzer Incorporates Recently Introduced DxC 500 AU Chemistry Analyzer Technology with Six Sigma Performance BREA, Calif. ,... Read More

WASHINGTON , June 24, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the second quarter 2024 on Tuesday, July 23, 2024 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations. The call and an accompanying slide presentation will be webcast on... Read More

WASHINGTON , June 19, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher" or the "Company"), a leading global life sciences and diagnostics innovator, today announced that Julie Sawyer Montgomery will succeed Joakim Weidemanis as Executive Vice President, Diagnostics effective as of July 1, 2024 . Mr. Weidemanis will support the transition over the next three months and will retire from Danaher on September 30,... Read More

Move reflects increasing investment in AI as driving force for innovation and productivity. Company will host Innovation Summit in December focused on AI in R&D. WASHINGTON , June 5, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a global science and technology innovator, today announced the creation of the new role of Chief Data & Artificial Intelligence (AI) Officer and the appointment of Dr. Martin Stumpe to the... Read More

The Danaher Beacon for Brain Injury Diagnostics seeks to identify mild Traumatic Brain Injury (TBI) earlier and more precisely. Scientists will evaluate new blood-based biomarkers using highly sensitive technology from Beckman Coulter Diagnostics. This approach could potentially be adapted for diagnosis of other neurological conditions. WASHINGTON , May 9, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a global... Read More

WASHINGTON , May 7, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair , will be presenting at the at the Bank of America Securities Health Care Conference in Las Vegas, Nevada on Tuesday, May 14, 2024 at 10:40 a.m. PT . The event will be simultaneously webcast on www.danaher.com . ABOUT DANAHER Danaher is a leading global life sciences and diagnostics... Read More

WASHINGTON , May 7, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.27 per share of its common stock, payable on July 26, 2024 to holders of record on June 28, 2024 . ABOUT DANAHER Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve... Read More

WOBURN, Mass. , May 3, 2024 /PRNewswire/ -- Curiox Biosystems Co. Ltd (Curiox), a leader in the innovation of life science research technologies, and Beckman Coulter Life Sciences , a global leader in laboratory automation and innovation, announce a strategic partnership to provide researchers with a one-stop solution for hands-free washed sample preparation for flow cytometry. The agreement combines the Laminar flow-based... Read More

WASHINGTON , April 23, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended March 29 , 2024. All results in this release reflect only continuing operations unless otherwise noted. Key First Quarter 2024 Results Net earnings were $1.1 billion , or $1.45 per diluted common share and non-GAAP adjusted diluted net earnings per common share were $1.92 . Revenues... Read More

WASHINGTON , March 21, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the first quarter 2024 on Tuesday, April 23, 2024 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations. The call and an accompanying slide presentation will be webcast... Read More

WASHINGTON , Feb. 27, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair , will be presenting at the TD Cowen Healthcare Conference in Boston, Massachusetts on Tuesday, March 5, 2024 at 11:10 a.m. ET . The event will be simultaneously webcast on www.danaher.com . ABOUT DANAHER Danaher is a leading global life sciences and diagnostics innovator, committed... Read More

WASHINGTON , Feb. 22, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (Danaher) announced today it has committed to set science-based greenhouse gas (GHG) emission reduction targets in line with the Science Based Targets initiative (SBTi), including a long-term target to reach net-zero value chain emissions by no later than 2050. Danaher's pledge encompasses Scope 1, 2 and 3 GHG emissions and complements its existing... Read More

WASHINGTON , Feb. 21, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.27 per share of its common stock, payable on April 26, 2024 to holders of record on March 28, 2024 . ABOUT DANAHER Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve... Read More

Danaher Beacon for Preclinical Drug Safety seeks to address major cause of failure in clinical trials Program will leverage automated liver organoid technology for drug toxicity screening Aims to expand genetic diversity of screening, accelerate therapy development, and help ensure patient safety WASHINGTON , Feb. 5, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a global science and technology innovator, today... Read More

WASHINGTON , Jan. 30, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the fourth quarter and full year 2023. All results in this release reflect only continuing operations unless otherwise noted. Key Fourth Quarter 2023 Results Net earnings were $1.1 billion , or $1.50 per diluted common share and non-GAAP adjusted diluted net earnings per common share were $2.09 . Revenues... Read More

New collaborative research center based at University of California, Berkeley , plans to develop platform approaches that can be easily modified to develop gene-editing medicines for hundreds of devastating illnesses Innovative model aims to dramatically reduce preclinical and clinical development time and expense for investigational rare disease therapies that currently struggle to attract funding Nobel laureate Doudna and... Read More

WASHINGTON , Jan. 8, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") announced that its President and Chief Executive Officer, Rainer M. Blair , will comment tomorrow on the Company's fourth quarter 2023 performance in a presentation at the J.P. Morgan Healthcare Conference at 2:15 p.m. ET . For the fourth quarter 2023, estimated revenues are anticipated to decrease in the low-double digit percent range... Read More

WASHINGTON , Jan. 2, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair , will be presenting at the J.P. Morgan Healthcare Conference in San Francisco, California on Tuesday, January 9, 2024 at 2:15 p.m. ET . The event will be simultaneously webcast on www.danaher.com . ABOUT DANAHER Danaher is a leading global life sciences and diagnostics innovator,... Read More

WASHINGTON , Dec. 21, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the fourth quarter 2023 on Tuesday, January 30, 2024 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations. The call and an accompanying slide presentation will be webcast... Read More

WASHINGTON , Dec. 6, 2023 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) ("Danaher") announced today it has completed its acquisition of Abcam plc (NASDAQ:ABCM) ("Abcam"). The acquisition of Abcam for $24.00 per share in cash was implemented by way of a Court-sanctioned scheme of arrangement under the UK Companies Act 2006 (the "Scheme") and the Scheme became effective in accordance with its terms on December 6, 2023 . As a... Read More

WASHINGTON , Dec. 5, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.24 per share of its common stock, payable on January 26, 2024 to holders of record on December 29, 2023 . ABOUT DANAHER Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to... Read More

WASHINGTON , Nov. 21, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair , will be presenting at the Evercore ISI HealthCONx Conference in Miami, Florida on Wednesday, November 29, 2023 at 3:00 p.m. ET . The event will be simultaneously webcast on www.danaher.com . ABOUT DANAHER Danaher is a leading global life sciences and diagnostics innovator,... Read More

WASHINGTON , Oct. 31, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher" or the "Company"), a leading global life sciences and diagnostics innovator, today announced that Christopher Riley has been appointed by its Board of Directors to be Executive Vice President of Danaher with responsibility for its Biotechnology business, effective January 1, 2024. Mr. Riley, currently Vice President and Group Executive of... Read More

WASHINGTON , Oct. 24, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the third quarter ended September 29 , 2023. Net earnings refer to net earnings attributable to common shareholders. Results for the third quarter include the operations of Veralto Corporation, which was spun-off to Danaher's shareholders on September 30, 2023 . Key Third Quarter 2023 Results Net earnings... Read More

WASHINGTON , Sept. 30, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that it has completed the separation of its Environmental & Applied Solutions segment, through the spin-off of Veralto Corporation. Veralto will begin "regular way" trading on the New York Stock Exchange on October 2, 2023 , under the symbol "VLTO." "Today marks an exciting milestone for Danaher. The successful spin-off of Veralto as... Read More

NEW YORK , Sept. 28, 2023 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, the S&P MidCap 400 and the S&P SmallCap 600 indices: Veralto Corp. (NYSE:VLTO) will be added to the S&P 500 effective prior to the open of trading on Monday, October 2 , replacing DXC Technology Co. (NYSE: DXC) which will be moved to the S&P SmallCap 600 effective prior to the open of trading on Tuesday, October 3... Read More

WASHINGTON , Sept. 26, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the third quarter 2023 on Tuesday, October 24, 2023 beginning at 8:00 a.m. ET and lasting approximately 1 hour. During the call, the company will discuss its financial performance, as well as future expectations. The call and an accompanying slide presentation will be webcast... Read More

New agreement aims to provide greater access to millions more high-quality tuberculosis (TB) tests for people living in the least developed countries where the need is most urgent. Enables the Global Fund to provide Cepheid's Xpert ® MTB/RIF Ultra diagnostic test cartridges for TB at cost, with no profit to Danaher. WASHINGTON , Sept. 19, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher"), a global science and... Read More

WASHINGTON , Sept. 12, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.27 per share of its common stock, payable on October 27, 2023 to holders of record on October 12, 2023 . ABOUT DANAHER Danaher is a global science and technology innovator committed to helping its customers solve complex challenges and improving quality... Read More

WASHINGTON , Aug. 31, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) will host a live video webcast of Veralto's Investor and Analyst Meeting on September 6, 2023 beginning at approximately 12:00 p.m. CT . The event, which will provide a comprehensive overview of Veralto and its operating segments, will be held at Videojet's facility in Wood Dale, Illinois and hosted by Veralto President & CEO Jennifer L. Honeycutt . A... Read More

WASHINGTON , Aug. 28, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher" or the "Company"), a global science and technology innovator, announced today that it has entered into a definitive agreement to acquire Abcam plc (NASDAQ: ABCM), a leading global supplier of protein consumables, pursuant to which Danaher will acquire all of the outstanding shares of Abcam for $24.00 per share in cash, or a total enterprise... Read More

WASHINGTON , Aug. 25, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) today announced that it expects to complete the previously announced separation of Veralto Corporation on September 30, 2023 , the first day of Danaher's fiscal fourth quarter. The Danaher Board of Directors has declared a pro rata dividend of all of the common stock of Veralto Corporation to Danaher stockholders of record as of the close of business... Read More

WASHINGTON , Aug. 16, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher" or the "Company"), the global science and technology innovator, today published its 2023 Sustainability Report which conveys the depth and scope of Danaher's sustainability program and highlights important milestones the Company achieved during the past year. "We are proud of the progress we are making across our sustainability initiatives.... Read More

ANAHEIM, Calif. , July 25, 2023 /PRNewswire/ -- Beckman Coulter, a clinical diagnostics leader, today revealed for the first time in North America the DxI 9000 Access Immunoassay Analyzer , addressing clinical laboratory demands for speed, reliability, reproducibility, quality, and menu expansion. The DxI 9000 Analyzer has... Read More

ANAHEIM, Calif. , July 25, 2023 /PRNewswire/ -- Beckman Coulter Diagnostics , a clinical diagnostics leader, received FDA clearance for its new DxC 500 AU Chemistry Analyzer, an automated chemistry analyzer, expanding the company's clinical chemistry offering and demonstrating ongoing commitment to product innovation in the in... Read More

WASHINGTON , July 25, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the second quarter 2023. Net earnings refer to net earnings attributable to common shareholders. For the quarter ended June 30, 2023 net earnings were $1.1 billion , or $1.49 per diluted common share and non-GAAP adjusted diluted net earnings per common share were $2.05 . Revenues decreased 7.5%... Read More

Collaboration Builds upon Fujirebio Expertise in Neurodegenerative Disease Assays and Beckman Coulter's High Sensitivity, High Throughput, Global Installed Base of Access Family of Immunoassay Analyzers BREA, Calif. and TOKYO , July 17, 2023 /PRNewswire/ -- Beckman Coulter Diagnostics, a clinical diagnostics leader, and Fujirebio, a leader in neurological markers and In Vitro Diagnostic (IVD) manufacturing, today announced a... Read More

WASHINGTON , June 20, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the second quarter 2023 on Tuesday, July 25, 2023 beginning at 8:00 a.m. ET and lasting approximately 1 hour. During the call, the company will discuss its financial performance, as well as future expectations. The call and an accompanying slide presentation will be webcast on... Read More

DxI 9000 Access Immunoassay Analyzer Boasts Industry's Highest Throughput per Footprint: Up To 215 Tests/Hour/Square Meter Innovations Bolster Assay Performance and Laboratory Productivity with New Analyte Processing and Detection Technology, Precision Sensors, Smart Algorithms, Remote Real-Time System Monitoring, and is the Only Immunoassay Analyzer with No Daily Maintenance i NT-proBNP Assay Now Available with Age-Based... Read More

WASHINGTON , May 9, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.27 per share of its common stock, payable on July 28, 2023 to holders of record on June 30, 2023 . ABOUT DANAHER Danaher is a global science and technology innovator committed to helping its customers solve complex challenges and improving quality of life... Read More

WASHINGTON , May 3, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair , will be presenting at the Bank of America Securities Health Care Conference in Las Vegas, Nevada on Wednesday, May 10, 2023 at 10:00 a.m. PT . The audio will be simultaneously webcast on www.danaher.com . ABOUT DANAHER Danaher is a global science and technology innovator committed... Read More

Will offer mRNA cGMP Production from Master Cell Bank to Drug Product Made Possible with Precision Nanosystems and Cytiva FARGO, N.D. , May 1, 2023 /PRNewswire/ -- Aldevron, a leading global manufacturer of DNA, RNA and proteins used in cell and gene therapies and vaccine development, will expand its mRNA production... Read More

WASHINGTON , April 25, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the first quarter 2023. Net earnings refer to net earnings attributable to common shareholders. For the quarter ended March 31, 2023 net earnings were $1.4 billion , or $1.94 per diluted common share and non-GAAP adjusted diluted net earnings per common share were $2.36 . Revenues decreased 7.0%... Read More

WASHINGTON , April 10, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its 5.00% Series B Mandatory Convertible Preferred Stock (the "Preferred Stock"), will automatically convert into shares of the Company's common stock on April 17, 2023 (the "Conversion Date"). The conversion rate for each share of Preferred Stock will be 5.0175 shares of the Company's common stock. Cash will be paid in lieu of... Read More

WASHINGTON , March 27, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the first quarter 2023 on Tuesday, April 25, 2023 beginning at 8:00 a.m. ET and lasting approximately 1 hour. During the call, the company will discuss its financial performance, as well as future expectations. The call and an accompanying slide presentation will be webcast on... Read More

WASHINGTON , March 7, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a global science and technology innovator, today announced a strategic partnership with the University of Pennsylvania ( Penn ) focusing on cell therapy innovation. The multi-year partnership aims to develop new technologies that will improve the consistency of clinical outcomes for patients and overcome manufacturing bottlenecks in the delivery of... Read More

WASHINGTON , Jan. 9, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") announced that its President and Chief Executive Officer, Rainer M. Blair , will comment tomorrow on the Company's fourth quarter 2022 performance in a presentation at the J.P. Morgan Healthcare Conference at 1:30 p.m. PT . For the fourth quarter 2022, estimated revenues are anticipated to increase in the low-single digit percent range... Read More

WASHINGTON , Jan. 3, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair , will be presenting at the J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023 at 4:30 p.m. ET . The audio will be simultaneously webcast and the presentation will be archived on www.danaher.com . ABOUT DANAHER Danaher is a global science and technology innovator... Read More

WASHINGTON , Dec. 27, 2022 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the fourth quarter 2022 on Tuesday, January 24, 2023 beginning at 8:00 a.m. ET and lasting approximately 1 hour. During the call, the company will discuss its financial performance, as well as future expectations. The call and an accompanying slide presentation will be webcast... Read More

WASHINGTON , Dec. 6, 2022 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.25 per share of its common stock, payable on January 27, 2023 to holders of record on December 30, 2022 . In addition, the Board of Directors has approved a quarterly cash dividend of $12.50 per share of its 5.00% Series B Mandatory Convertible Preferred... Read More

WASHINGTON , Nov. 22, 2022 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair , will be presenting at the Evercore ISI HealthCONx Conference on Wednesday, November 30, 2022 at 10:30 a.m. ET . The event will be simultaneously webcast on www.danaher.com . ABOUT DANAHER Danaher is a global science and technology innovator committed to helping its customers solve... Read More